Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute identify a molecular pathway to boost vaccine responses in the elderly.

A new study by Professor Katja Simon and colleagues published in Molecular Cell shows that spermidine, a naturally occurring metabolite found in most human cell types, boosts antibody production in both old mice and immune cells from the elderly. The findings may offer an approach for improved vaccination strategies for older people who are less responsive to vaccines and more vulnerable to infection.

The team found that spermidine kick-starts the immune system through autophagy, a cellular recycling pathway that declines as cells age.

Katja explains "Our data reveal a novel molecular pathway where spermidine adds an essential modification to the protein, eIFA5, which is needed to produce the molecule TFEB, a master regulator of autophagy".

The authors have previously shown that spermidine targets autophagy to restore the function of old T cells in the immune system. The new work demonstrates a broader role for spermidine in rejuvenating the immune system which includes long-lived B cell responses, the main correlate of protection offered by vaccines. These data add to growing evidence from mice that spermidine protects against a range of age-associated defects, including cardiovascular disease and cognitive decline, by stabilising autophagy.

"Spermidine levels and autophagy are both known to decline with age. Our work links these two observations and explains why cellular autophagy declines with age and the downstream effect in ageing tissues. The data reveals multiple promising targets to restore autophagy levels and tissue functions in the elderly, to treat age-related disease" says Katja.

The research was funded by the Wellcome Trust, China Scholarship Council and Elysium Health.

Similar stories

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.